Regeneron's (REGN) Libtayo has been recommended for EU approval by the CHMP for the adjuvant treatment of CSCC with a high risk of recurrence following surgery and radiation
17 Oct 2025 - 12:30- Equities- Source: Globe Newswire
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts